Our live Investing Matters Podcast Special which took place at the Master Investor Show discussing 'How undervalued is the UK stock market?', has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Going no where while the 100k...50k seller is about. Being selling for a long time. Another 100k at the bottom. Cheap buy out. Can't be for a dear one. Every bit of good news and the SP sinks again. IMO
Ray
AvidiMab bolted on to Checkpoints that would be a £1 a share on its own.
If any of us is feeling down we should just contemplate that concept becoming reality. If that doesn’t lift your spirits nothing would.
This has been said before, ‘ we are on the cusp of Scancell’s first domino dropping and there could be many to follow ‘.
I wonder what Scancell are currently up to with Avidimab.
https://www.scancell.co.uk/Data/Sites/1/media/publications/posters/kaira-et-al-2022.pdf
"Future work
validation in other immune co-agonists that rely on clustering for activity and/or
checkpoint inhibitors (CPIs) that rely on increased residence time"
The remark on increased residence time for CPIs is interesting. Some of the CPIs must be getting towards the end of their patent life. No doubt big pharma will have ideas about how to extend the patents. However, if Scancell were to prove that Avidimab could enhance the effect of CPIs and , as a bonus, extend the patent life, that may be very attractive to them.
Chester...they don't really "push" Avidimab in that presentation I don't think .
Why state it as preclinical when it was used in the Covidity trial ???
Nothing about Covidity in page 17 where Avivimab is presented.
Chester....one day nearer the red dot then 🤞
Guess that one of the positives ...Scancell has a multi product pipeline!
Don't forget this overview written and presented January 2024 interim results giving a great breakdown of where we are up to
https://www.scancell.co.uk/Data/Sites/1/media/fininfo/2024/scancell-interim-results-fy-2024.pdf
@violindog
Nope not a word, but that's what NDA's do.
We will not know until the evaluation is complete and a deal is struck.
Could happen any day and if it does that will be a big step forward for AvidiMab and Scancell. 🤞
Chester, you would certainly think that some pharma may / should be interested in the product. Was there not talk of it being able to extend patents? Is there any hint from Scancell that Avivimab is being evaluated ?
Another interesting RNS from them today. As I said... not invested but I'm interested to how the SP reacts to the results and "management " of the BEXMAB news by FARN. Will Sclp SP follow a similar path ? 🤞
The steps forward for AvidiMab :
Proof of Concept ✔️ Lab Work
In Human Trial ( Tox Safety ) ✔️ Covidity
Proof of Enhanced Avidity of an existing Mab ? ( Taking Place )
There must be NDA’s in place and Third Party lab trials happening right now.
What we are waiting for is just one of the evaluations to be successful and the first deal over the line. When that happens there will be more global interest.
Get that first one done and we are off to the races.
Hi Chester/Ray
Avidimab: bolt on tool. Yes I agree too.
I take comfort that Avidimab is in that space... SEAGEN and or GenMab may admire or appreciate it. If a deal were possible, could it be from this direction?
Starts today good luck to both
BIO-Europe Spring in Barcelona, Spain from 18-20 March
Mandeep Sehmi, Head of Business Development and Mireille Vankemmelbeke, PI at Scancell will be attending the conference.
BOJO thanks for your 09.13 and Ray for 11.15 and 11.35 giving us a really helpful and clear explanation of Avidimab - a good refresher for oldies and an essential for newbies.
So come on Genmab and all !!
Markus 2 other side interesting points :
Avidimab explained well. It could improve and potentially extend patent life for big Pharma products. In 2022 Trinity thought Avidimab could have peak sales of £8.5 billion and a royalty for us of 8%.
The early Scib-1 results 2018
I am thinking about the cash the Genmab have now accumulated thanks to their clever approach to their KYSO ( knock your socks off IP , some thought that wa joke ? clearly not ) Ip
Now he's assuming other people's gender. (Presuming he's also actually a he and not an amoeboid zingatularian or something)
Can’t see any commas in the wrong place though Ray 😂
"herself" not "itself"
😂
Exactly chester.
Lindy itself thinks it could benefit any mAb.
It may be that Scancell's current strategy for Avidimab is to just let the evidence accumulate when Avidimab is used in combination with other agents.
Avidimab had its first outing with the Covidity trial. It may be impossible to measure the effect of Avidimab in this trial, since there was no cohort without Avidimab.
The SCIB1 and iSCIB1+ trial may give a better indication of the effect Avidimab has.
It's worth bearing in mind how Avidimab came about. When Gylcans mAbs were humanised, they lost the ability to bind to their target. Lindy's team then worked to find what it wat in the mouse mAb that gave the strong binding. Once isolated, this was added to the humanised mAb and, hey presto, the humanised mAb regained strong binding.
Genmab will be one company that will be well aware of Avidimab. Possibly they are the most likely to add Avidimab to one of their own mAbs in development and be the first to execute an Avidimab deal.
We all hope that the first such deal is the prelude to an avalanche of deals
So are we better thinking of AvidiMab as a bolt-on tool ?
Morning bojo
You make the point:
"Conclusion: Avidimab needs its own trials. It could prove itself to be a successful mab in its own right;"
It is not possible to trial Avidimab on its own since it is an addition to a mAb not a mAb in its own right.
When added to an existing mAb, it heightens the chances of the existing mAb to bind to its target.
"...and at some point it needs to realise value for the main assets".
This. Otherwise what is the point?
To be fair though it seems like people/connections are in now finally place. Just please get a move on please Scancell!
Morning Bojo;
The point you highlight is valid the more you do to improve the Science by fine tuning and addition of extra bits like Avidmab then the more difficult it is to evaluate the individual effect of relative synergies.
No one disputes SCLP doing everything it can to improve the outcomes and of course if successful will increase the value but the history here is of continuous improvement and at some point it needs to realise value for the main assets.
Personally I am hopeful that the next set offSCIB1 Combo results will firmly put us on that pathway
I see Avidimab as a pre-clinical asset.
As we know it is currently involved in SCOPE. If we assume that iSCIB1+ takes over from SCIB1 and provides above the assumed 70% ORR and a durable response, we must accept that Avidimabs role is not stand alone in that instance. It will have become part of the package iSCIB1+, which imo would be successfully demonstrated as THE stand alone asset. So Avidimab plus something else makes a stand alone asset = Avidimab makes a hybrid but is not the actual asset.
So my question is, despite having a significant role in say a SEAGEN or Scancell trial, why on earth would either company water down the subject of there own successful clinical asset (SEA-CD40 or iSCIB1+) by saying that it was due in part to Avidimab? Remember the objective of the trial being to prove the stand alone asset, not the delivery method etc etc.It is wholly more likely in my view that both SEAGEN and Scancell would be encouraged but still be unable to prove the exact role Avidimab plays without a robust trial of its own.
Finally, it may well become important for the regulatory bodies to understand the role Avidimab plays... This is because if it is not clearly defined, it could be used to boost poor drug candidates results. If for instance FDA were able to understand definitively what it does, then it would make distinguishing trial results clearer.
Conclusion: Avidimab needs its own trials. It could prove itself to be a successful mab in its own right; a successful asset in its own right. Maybe more likely in combination? This would mean it could be worth billions. But until then, the only way forward is if there are brave maverick entrepreneurial types willing to take it on. Or the more sensible types that will give it a six month assessment and maybe a milestone deal?
Anyway, these are not my definitive thoughts, just spit balling so feel free to tell me I am wrong!
For those of us with less patience, isn't the fact Sath wasn't offered (?) shares or options a good sign i.e. indicates a closed period?
Similar to others, I don't see any offers coming until we have much more trial data...
Also, does Sath have any shares/options? I don't see any mention. I suspect no CFO would sit out buying shares/receiving options - if a partnership deal/TO was in the offing (obviously taking into account, quiet periods & access to information).. If we see Sath take up some shares/options when he is able to do so, that is a solid sign...